|
KMID : 1035620230110030117
|
|
Allergy Asthma & Respiratory Disease
2023 Volume.11 No. 3 p.117 ~ p.125
|
|
|
KAAACI Allergic Rhinitis Guidelines: Part 1. Update in pharmacotherapy
|
|
Kim Min-Ji
Kang Sung-Yoon
Yang Song-I
Lee Il-Hwan
Ryu Gwang-Hui
Kim Mi-Ae
Lee Sang-Min
Kim Hyun-Jung
Park Do-Yang
Lee Yong-Ju
Kim Dong-Kyu
Kim Do-Hyun
Jun Young-Joon
Park Sang-Chul
Kim Bong-Seong
Chung Soo-Jie
Lee Hyun-Jong
Kim Hyo-Bin
Choi Jeong-Hee
Choi Gil-Soon
Yang Hyeon-Jong
Kim Soo-Whan
|
|
|
Abstract
|
|
|
|
The prevalence of allergic rhinitis (AR) and the socioeconomic burden associated with the medical cost and quality of life of AR have progressively increased. Therefore, practical guidelines for the appropriate management of AR need to be developed based on scientific evidence considering the real-world environment, values, and preferences of patients and physicians. The Korean Academy of Asthma, Allergy and Clinical Immunology revised clinical guidelines for AR to address key clinical questions of the management of AR. Part 1 of the revised guideline covers the pharmacological management of patients with AR in Korea. Through a meta-analysis and a systematic review, we made 4 recommendations for AR pharmacotherapy, including intranasal corticosteroid (INCS)/intranasal antihistamine combination therapy, oral antihistamine/INCS combination therapy, leukotriene receptor antagonist treatment in AR patients with asthma, and prophylactic treatment for patients with pollen-induced AR. However, all recommendations are conditional because of the low or very low evidence of certainty. Well-designed and strictly executed randomized controlled trials are needed to measure and report appropriate outcomes.
|
|
|
KEYWORD
|
|
|
Allergic rhinitis, Asthma, Guideline, Drug, Pharmacotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|